Marc Hummersone has over 20 years of project and managerial experience in both big and small technology companies, including industry leaders AstraZeneca, General Electric Healthcare, and Cytiva. He has a broad experience base across a wide range of technologies, including the development of novel chromatographic media for the purification of complex biological feed streams as well as drug discovery and development. He was a key contributor to the development of the Fibro chromatography family of products, which resulted in the acquisition of Puridify by GE Healthcare in 2017. Additionally, he was a key part of the management team that validated the concept of synthetic lethality and identified and developed Lymparza, an approved drug for the treatment of BRCA-mutated advanced ovarian cancer, which resulted in the acquisition of KuDOS Pharmaceuticals in 2005 by AstraZeneca. Marc has held positions including company director, Chief Scientific Officer, and department director. He gained his Ph.D. and postdoctoral experience in chemistry, which was focused on the total synthesis of complex natural products, at University College, London.
.svg)
